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Abstract
Within paediatric populations there may be distinct age groups characterised by different exposure-response relationships.
Several regulatory guidance documents have suggested general age groupings. However, it is not clear whether these
categorisations will be suitable for all new medicines and in all disease areas. We consider two model-based approaches
to quantify how exposure-response model parameters vary over a continuum of ages: Bayesian penalised B-splines and
model-based recursive partitioning. We propose an approach for deriving an optimal dosing rule given an estimate of how
exposure-response model parameters vary with age. Methods are initially developed for a linear exposure-response model.
We perform a simulation study to systematically evaluate how well the various approaches estimate linear exposure-
response model parameters and the accuracy of recommended dosing rules. Simulation scenarios are motivated by an
application to epilepsy drug development. Results suggest that both bootstrapped model-based recursive partitioning
and Bayesian penalised B-splines can estimate underlying changes in linear exposure-response model parameters as well
as (and in many scenarios, better than) a comparator linear model adjusting for a categorical age covariate with levels
following ICH E11 groupings. Furthermore, though the Bayesian penalised B-splines approach consistently estimates
the intercept and slope more accurately than the bootstrapped model-based recursive partitioning. Finally, approaches
are extended to estimate Emax exposure-response models and are illustrated with an example motivated by an in vitro
study of cyclosporine.
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1 Introduction
Children of different ages given a new medicine may be
characterised by different dose-exposure and exposure-
response (E-R) relationships due to age related
differences in growth, development and physiological
differences1. Several regulatory guidance documents
have suggested general age groupings, such as the
International Conference on Harmonisation (ICH) E11
document1, which suggests one possible categorisation:
preterm newborn infants; term newborn infants (0 to
27 days); infants and toddlers (28 days to 23 months);
children (2 to 11 years); and adolescents (12 to 16-18
years, depending on region). The National Institute
of Child Health and Human Development (NICHD)
guideline, suggests similar age groups, but with extra
splits at 1 and 6 years. This paper aims to estimate
the E-R relationship in children and to identify age
groupings which define practical and effective dosing
rules.
An understanding of how the E-R relationship of
a drug varies with age will inform whether and how
we leverage adult data to support drug development
in children. Hampson et al.2 reviewed paediatric
investigation plans (PIPs) and found that it was
common to plan to identify paediatric doses by
matching target adult exposures. This is an appropriate
dose-finding strategy if E-R relationships are similar
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in adults and children. This assumption might be
justified for some paediatric subgroups but not others.
For example, Takahashi et al.3 concluded that whilst
pubertal (12 to 18 years) and adult patients had similar
PD responses to long-term warfarin therapy, there were
differences between pre-pubertal (1 to 11 years) patients
versus pubertal and adult patients. If E-R relationships
can be assumed to be similar across age groups, it may
be appropriate to make a complete extrapolation of
efficacy data from one age group to another, so that
only dose-exposure data are needed in the unstudied
age group to identify doses producing exposures known
to be efficacious in the studied age group2,4. However,
if E-R relationships cannot be considered similar, a
partial extrapolation approach4 may be considered,
where dose-exposure and E-R data may be accrued
in specified age groups to confirm differences in E-R
relationships and confirm dosing.
One common approach to modelling nonlinear E-R
relationships is the Emax model5. Thomas et al.6
show that the Emax model provides good fit to the
dose-response relationship of almost all compounds and
diseases in the time window they studied. Parkinson
et al.7 developed a sigmoid Emax model for the
relationship between dapagliflozin exposure and
urinary glucose excretion for adult and paediatric
patents with type 2 diabetes mellitus. After accounting
for significant covariates (e.g. sex, race, baseline fasting
plasma glucose), further covariates were included for
paediatric patients which failed to improve model fit.
The authors took this as evidence that adult and
paediatric patients had similar E-R relationships. Earp
et al.8 used E-R modelling and exposure matching
analyses to estimate paediatric doses for esomeprazole
for the treatment of gastroesophageal reflux disease.
The authors modelled E-R relationships of intragastric
pH for adults and children separately and concluded
similarity of E-R based on a visual inspection of fitted
E-R relationships. In this paper, a more quantitative
approach to evaluating differences between E-R
relationships is taken using sophisticated modelling
approaches.
Age groups characterised by different E-R
relationships can be considered as distinct subgroups.
Lipkovich et al.9 reviewed methods for the identification
and analysis of subgroups in clinical trials. Ondra et
al.10 reviewed methods for designing and analysing
clinical trials that aim to investigate differences in
treatment effects across subgroups. In this paper, we
consider two model-based approaches to quantifying
how E-R model parameters vary over a continuous age
range: Bayesian penalised B-splines11, and model-based
recursive partitioning (MOB)12,13 which is used to
fit model-based trees to bootstrapped samples of the
E-R data. Based on estimates of how E-R model
parameters vary with age, we propose an approach
to identify the age groups and exposure levels that
define a dosing rule which is optimal for targeting a
certain level of response; definition of the dosing rule
is then completed by using the exposure levels and
estimated dose-exposure relationship to make dosing
recommendations for each age group. The estimated
dose-exposure relationship is not considered in this
paper.
Thomas et al.14 use MOB to estimate patient
subgroups with different dose-response curves, and
apply this method to data from a dose-finding trial.
In this paper, we focus on estimating age groups with
different E-R relationships since in practice, when
seeking to relate dose to response, a two-step process
relating dose to exposure then exposure to response is
often adopted. For example, the ICH E4 guidance15
states that E-R information can help to identify a
range of concentrations likely to lead to a satisfactory
response, which can in turn inform dose selection.
While parameters of the dose-exposure relationship
are expected to depend on age, for some medicines
parameters of the E-R relationship are expected to
remain stable across age groups. In such cases, the two-
step modelling process can be advantageous because
it enables separate modelling of the dose-exposure
and E-R relationships, which allows for changes due
to age to be captured in each relationship separately.
In a simulation study to compare the performance
of the two-step and single stage approaches to dose
finding, Berges and Chen16 found that the two-step
approach resulted in more precise E-R model parameter
estimation and more accurate dose selection, although
gains depend on properties of the drug, trial design
features and the target response.
Pharmacokinetics is the study of the time course
of drug levels in the body and the mathematical
modelling of such data17. Population-PK models are
an extension of PK modelling, studying PK at the
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population level and modelling data from all individuals
simultaneously18. Hsu19 found that in scenarios with
increased intrinsic pharmacokinetic (PK) variability,
E-R modelling has advantages for dose selection over
dose-response modelling, provided measurement error
for exposures is small. As an example of a two-stage
approach to selecting a dosing rule, Schoemaker et
al.20 developed a population PK model to describe the
relationship between brivaracetam dose and plasma
concentration in adults with partial onset seizures, and a
population pharmacokinetic-pharmacodynamic model
to describe the relationship between brivaracetam
plasma concentration and daily seizure counts. The
authors then simulated from these models to estimate
the relationship between dose and response, enabling
them to identify a dose range producing the maximum
response.
This paper proceeds as follows. Section 2 gives a
motivating example while Section 3 defines two E-R
models. In Section 4, we introduce the methods that will
be used to estimate parameters of E-R relationships.
Section 5 proposes an approach for using fitted E-R
models to identify practical dosing rules for children.
We use simulation to evaluate the performance of E-R
modelling approaches and the operating characteristics
of the dosing rule algorithm. The design of the
simulation study is described in Section 6 and the results
are presented in Section 7. An example illustrating how
the E-R modelling approaches can be applied to non-
linear models is given in Section 8. The paper concludes
with a discussion in Section 9.
2 Motivating example
We motivate the work that follows by considering
the development of epilepsy medicines for paediatric
patients with partial onset seizures. Girgis et al.21 study
both monotherapy and adjunctive therapy with the
anti-epileptic drug topiramate, whilst Nedelman et al.22
consider adjunctive therapy with oxcarbazepine. For
adjunctive therapy, Girgis et al.21 and Nedelman et
al.22 take response, Y = log{Z + 110}, to be the log-
transformed percent change from baseline in seizure
frequency, where Z is the percent change from baseline
in seizure frequency. The response, Y , is assumed
to be normally distributed and a linear function of
exposure, measured by the average steady-state trough
concentration (Cmin). Girgis et al.
21 and Nedelman
et al.22 evaluate the similarity of E-R relationships in
adults and children on adjunctive therapy with the aim
of justifying the use of extrapolation to support the
approval of monotherapy in children. The models and
the parameter estimates21 will be used to inform the
design of realistic simulation scenarios.
3 Exposure-Response models
We start by considering a linear model for the E-
R relationship. Suppose E-R data are available from
a single study which recruited children aged 0 to 18
years and let Yi represent the response of subject i, for
i = 1, . . . , N . If the E-R relationship does not depend
upon age, we could model it as:
Yi = γ0 +
P∑
p=1
γpxpi + γCCi + i,
where Ci is a measure of drug exposure (such as Cmin),
x1i, . . . , xPi are other covariates influencing response
(such as body weight), and i ∼ N(0, σ2) is a random
error term. We consider the situation where the E-R
relationship may differ between age groups, that is, γ0
and γC are functions of age (A):
Yi = γ0(Ai) +
P∑
p=1
γpxpi + γC(Ai)Ci + i. (1)
In Section 4 we will consider different approaches for
parameterising γ0(Ai) and γC(Ai).
Non-linear Emax models are often used to represent
the E-R relationship23. For example, it could be
modelled by a sigmoid Emax model:












where for subject i, aged Ai years old, γ0(Ai) is the
intercept, Emax(Ai) is the maximum effect attributable
to the drug, EC50(Ai) is the concentration of the drug
that produces half of the maximum effect, and δ(Ai)
(the Hill parameter) governs slope steepness. Here, four
of the model parameters may potentially depend upon
age.
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4 Estimating the exposure-response
relationship
In this section we describe three E-R modelling
approaches that can be applied when we assume the
E-R relationship follows model (1) with age-dependent
intercept and slope. These methods are: linear regression
with categorical covariates for age groups; MOB
and partially additive linear model (PALM) trees;
and Bayesian penalised B-splines. We highlight where
methods can be applied more generally with non-linear
E-R models. A worked example illustrating how each
method can be applied to fit a linear E-R model is given
in Supplementary Appendix A.
4.1 Linear model fit with categorical age
covariates
If we knew that the age groups defined by different E-R
relationships were (a0 = 0, a1], (a1, a2], . . . , (aH−1, aH =













where Ah is the interval (ah−1, ah]; IAh(Ai) is
an indicator function (1 if Ai ∈ Ah, 0 otherwise);
γA,2, . . . , γA,H are the main effects of the age groups;
and γI,2, . . . , γI,H are the interactions between age
group and exposure. Fitting this model permits
estimation of age group specific intercepts and slopes.
We include this simple model as a benchmark
for comparison with other more complex modelling
approaches. Unlike the other methods we consider,
this approach requires that age groups be pre-specified
rather than estimating them from the data.
4.2 MOB and PALM trees
Building on model (3), MOB allows data to be split
into groups based on partitioning variables, with each
subgroup characterised by its own parametric model13.
We implement MOB using age as the only partitioning
variable. The MOB algorithm we use comprises the
following steps13: Fit a parametric model to the
dataset, finding parameter estimates by minimising an
objective function; test whether the model parameters
significantly change with age using a generalized M-
fluctuation test13,24 which assesses whether the scores
of the model systematically deviate from 0 with age;
partition the model into two subgroups with respect
to age by finding the value of age which minimises
an objective function segmented at this split point;
repeat the fitting, testing and splitting procedure in
each identified age group until no significant changes
are found in the model parameters over age within each
group. In our subsequent examples, the parametric
model will be taken to be a linear model, where the
parameters of interest are the intercept and slope. The
MOB algorithm13 can be implemented using the ‘mob’
function found in the ‘partykit’ package13,25 in R26.
As MOB allows subgroups defined by any parametric
model, non-linear models (such as Emax models) are
possible.
PALM trees are a variation of MOB, allowing
for global parameters which remain constant across
subgroups. However, PALM trees are restricted to
generalised linear models (GLM)12. For our linear
model example with outcome Yi and partitioning age
variable Ai, PALM trees can contain globally fixed
linear effects γ1, . . . , γP for covariates x1i, . . . , xPi
and subgroup-wise varying linear effects γ0(Ai) and
γC(Ai), as in equation (1). PALM trees use the MOB
algorithm described above to identify age groups with
distinct GLMs. In order to allow for global parameters
which remain constant across age groups, an EM-type
algorithm is used. This iterates between estimating the
global effects, γ1, . . . , γP , for the current PALM tree
and estimating the PALM tree (using the above MOB
algorithm) for a given set of global effect estimates,
γˆ1, . . . , γˆP . The algorithm can be implemented in R
26
using the ‘palmtree’ function found in the ‘partykit’
package12,25. We implement PALM trees with the
default tuning parameters, i.e. a significance level of
0.05 and no maximum tree depth. An advantage of tree
based methods is the easy to understand output: each
final partitioned subgroup of the tree represents an age
group, with model parameter estimates given for each
group.
We implement MOB and PALM tree approaches
using bootstrap aggregating27 to improve the accuracy
and precision of age-specific E-R model parameter
estimates and reduce overfitting. The E-R data are
bootstrapped and each bootstrap sample is used to fit
Prepared using sagej.cls
Wadsworth et al. 5
a MOB or PALM tree. From each bootstrap tree fit,
estimates of age-specific model parameters (intercept
and slope) can be evaluated for a grid of ages covering
the interval [0, 18] years. For each grid point in turn,
we then aggregate across the bootstrap samples and,
applying linear interpolation to the average age-specific
parameter estimates, can thus obtain an estimate of the
E-R intercept or slope for any given age. The important
aspect to note here is that no parametric assumptions
are made about the form of the relationship between
each model parameter and age. One disadvantage of
this is that these relationships cannot then be easily
recorded in a closed form for future reference.
We fit linear E-R models using PALM trees in Section
6 because we also consider the case of having an
additional global covariate whose effect is independent
of age, which we present in Supplementary Appendix B.
In Section 8, we fit non-linear E-R models using MOB.
4.3 Bayesian penalised B-splines
Splines define flexible regression models by joining
smooth curves (differentiable at every point) together
at knot points28. An E-R model parameter that can
be written as a smooth function of A, f(A), can be
modelled as a spline. Here, we will consider the penalised
B-splines developed by Eilers and Marx11. B-splines can
be written as a linear combination of B-spline basis





A B-spline basis function of degree d consists of
d+ 1 polynomial curves of degree d, each joined in
sequence11. The degree of the B-spline basis controls
how differentiable the spline is and can influence the
smoothness of the spline. We implement B-splines of
degree 2 as in the examples we have considered we gain
little in terms of smoothness for the added complexity
of using degree 3 B-splines. We therefore fit linear E-R









βCjBj(Ai; d = 2).
We set J = 26 given our choice of degree and number of
knots: five equally spaced knots within each of the four
ICH E11 age groups (not including pre-term newborn
infants), knots at each age group boundary, along with
two external knots below age zero and two above 18
years. We use the function ‘splineDesign’ in the R
package ‘splines’26 to contruct our 26 B-spline basis
functions. Further details of how the B-spline basis
functions are constructed can be found in Bowman and
Evers28. Note that for penalised B-splines, Eilers and
Marx11 recommend using equidistant knots and suggest
that there are no gains to be made from using unequally
spaced knots, as the penalty smooths any sparse areas.
However, we specify knots using the prior information
on potential age groupings that is contained in the
ICH E11 guidance document1. By specifying an equal
number of knot points across each ICH E11 age group,
knots are more densely spread across age ranges where
model parameters are expected to change most rapidly
with age. A sensitivity analysis to explore the impact
of knot placement would be appropriate in many cases.
For penalised B-splines, a roughness penalty is
used to control the smoothness of the estimated
spline, rather than the choice of knot location and
number11. In a Bayesian context, penalised B-splines
are implemented placing random walk priors on the
B-spline coefficients28,29. For example, to penalise
differences between adjacent B-spline coefficients, first-
order random walk priors are used:
β0,j |β0,j−1 ∼ N(β0,j−1, τ20 ), for j = 2, . . . , J
βC,j |βC,j−1 ∼ N(βC,j−1, τ2C),
with β0,1 ∼ N(0, 100) and βC,1 ∼ N(0, 100). This
penalises B-spline coefficients by shrinking towards a
common constant28, which is desirable in our context
since we anticipate that there may be age ranges on
which a model parameter is fairly stable followed by
periods of rapid change. We stipulate diffuse Inverse-
Gamma(1, 0.005) priors for τ0 and τC , similar to Lang
and Brezger (2004)29 who place an Inverse-Gamma
prior on the variance of the random walk prior. We
do not weight τ20 and τ
2
C by the distance between
successive knot points, as suggested by Kneib et al.30,
to allow larger prior variation when there are larger
steps between knots. This is because in our setting, we
have purposefully placed knots closer together over age
intervals where the most rapid changes with age are
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anticipated.
We fit the Bayesian penalised B-splines model using
Hamiltonian Monte Carlo, calling Stan31 from R26
using the RStan package32, and running three chains
with a default thinning rate of one for 3000 iterations,
1500 of which are discarded as burn-in samples.
Following equation (4), the posterior means of the
B-spline coefficients are multiplied by the B-spline basis
functions to estimate the B-spline for the respective
E-R model parameter.
Bayesian penalised B-splines are a very flexible
modelling approach, with the capacity to be used to
represent the parameters of any parametric E-R model.
The ability to write the relationship between E-R
parameters and age in a simple form, as in equation
(4), means it is easy to record and communicate the
estimated relationship. However, Bayesian penalised B-
spline models can comprise many parameters which can
make them computationally expensive to fit.
5 Dosing recommendations
5.1 Optimisation criterion
We could use the modelling approaches described
in Section 4 to derive personalised dosing
recommendations tailored to a patient’s exact age
and baseline covariates. However, for practical reasons,
we seek to identify dosing rules based on wider age
subgroups. As outlined in Section 1, we focus on
identifying age groups and exposure levels targeting
a certain level of response, assuming that in a second
step we could use a PK model to link each target
exposure to dose. Therefore, we use ‘dosing rule’ as
a short-hand to refer to a set of age groupings and
corresponding target exposures. First, we derive target
exposure levels for up to K age groups of children.
For practical reasons, K would likely be small, e.g.
K = 5 in the ICH E11 guideline1. When defining the
target exposure for each age group, we would like to
minimise the difference between the expected response
and a target response denoted by Y ∗. For the epilepsy
example, a 50% change in seizure frequency from
baseline would be an appropriate target response, so
that Y ∗ = log(−50 + 110).
We derive dosing rules assuming the E-R model
and parameter estimates (maximum likelihood for the
frequentist approaches, posterior means for the Bayesian
penalised B-splines) are identical to the true model
and parameter values. Given a proposed age grouping,
let Ck denote the target exposure for the kth age
group (ak−1, ak] needed for a patient aged (ak−1 +
ak)/2 years to have expected PD response equal to
Y ∗. Furthermore, define Da = |E[Y | A = a,C = Ck]−
Y ∗|. If the E-R model adjusts for a set of baseline
covariates, expectations of Y are calculated conditioning
on average covariate values at age A = a, while Ck is
calculated for a patient with average covariate values
at age (ak−1 + ak)/2. One approach would be to find
the dosing rule minimising the objective function F =∫ 18
0
Da da, where rules minimising F minimise the total
absolute difference between the expected response and
Y ∗. F weights equally the performance of the dosing rule
at every age. This is undesirable in our context since if
E-R model parameters do depend on age, it may be
reasonable to expect parameters to change rapidly over
short intervals (i.e. between 0 - 2 years) and remain
fairly stable across the adolescent age range. Minimising
F would favour rules which dose most ages effectively,
where inaccurate dosing over narrow age intervals would
not be seriously penalised. However, our aim is to ensure
all ages are dosed appropriately. With this in mind, we


















where a∗1 < a
∗
2 < . . . < a
∗
P are fixed and pre-specified
age boundaries and may be based on regulatory
guidance, such as the ICH E11 guideline1 or the NICHD
guideline33. We define these boundaries in line with the
NICHD guidelines. Finding dosing rules which minimise
G means that we give equal weight to the performance
of the dosing rule in a number of paediatric age groups
considered as our best prior guesses.
5.2 Identifying an optimal number of age
groups in our dosing rule
Define ΛK = (a0, . . . , aK) as the vector of age
boundaries defining the optimal dosing rule with K
groups; CK as the vector of target exposures; and G∗K
as the minima of G for K age groups. Furthermore,
let Kmax denote the maximum number of age groups
considered to be plausible or workable in practice,
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which would be pre-specified based on feedback from
clinicians. We use the following algorithm to define a
paediatric dosing rule:
1. Begin with K = 1 age group;
2. For K age groups, search over configurations of
ΛK to find the dosing rule minimising GK ;
3. Save G∗K , Λ
∗
K , and C∗K ;
4. Repeat steps (2) and (3), successively increasing
K by one until K = Kmax.
The minima G∗1, ..., G
∗
Kmax
can be compared to see if
increasing K always produces a worthwhile increase in
the accuracy of the dosing rule. The optimum value
of K, balancing the trade-off between complexity and
accuracy, is denoted by K∗. In some scenarios, a more
automated approach to selecting K∗ is possible. In these
cases, for each K = 1, ..., 5, we propose calculating the
percentage difference between G∗K+1 and G
∗
K . The value
of K where the percentage change is less than c = 25%
is taken as K∗. The arbitrary choice of c used here is
intended to illustrate one possible approach and will be
adopted in the simulation study described in the next
section.
6 Design of the simulation study
We performed a simulation study to explore the
performance of the modelling approaches described in
Section 4 and the approach of Section 5 for defining
dosing rules. We consider a range of data generation
scenarios for the linear model described in Section 3.
For the categorical age covariates model, we follow
the ICH E11 age groups to fix the age intervals as
A1 = (0, 28/365],A2 = (28/365, 2],A3 = (2, 12] and
A4 = (12, 18] in equation (3), across all scenarios.
We simulate studies enrolling 25 subjects
into each of four ICH E11 age groups,
(0, 28/365], (28/365, 2], (2, 12], (12, 18], excluding
preterm newborn infants. Within age group (ai−1, ai],
the age of patient i is sampled from a Uniform(ai−1, ai)
distribution. We consider 11 scenarios, as illustrated in
Figures 1 and 2, for how E-R model parameters vary
with age. More detail on these scenarios is provided in
Supplementary Table S1, Supplementary Figure S9 and
Appendix A. We only consider scenarios where the E-R
intercept and slope change monotonically with age,
since these differences are most realistic in the context
of the epilepsy example.
Figure 1. Plot showing how the intercept of the E-R model
changes with age in simulation scenarios 1-11.
Figure 2. Plot showing how the slope of E-R model changes
with age in simulation scenarios 1-11.
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We measure exposure by Cmin. Following Wadsworth
et al.34, we sample log(Cmin) from a N(log(2.94), 0.921)
distribution, truncating samples above by log(17.27)
to avoid excessively high concentrations. We sample
random errors from a N(0, 0.02) distribution. These
simulated values are used to generate patient responses,
Yi, according to equation (1). We simulate 1000 data
sets for each scenario and approach using the statistical
software R26.
6.1 Evaluating different approaches to
modelling the E-R relationship
We use the following measures to compare the modelling
approaches. Define A as a grid of Q = 40000 equally
spaced ages between 0 and 18 years. For each age,
Aq ∈ A, we first measure how well each of the methods
has estimated the true intercept and slope parameters.
We do this by comparing the true parameters, γ0(Aq)
and γC(Aq), with our estimates of the parameters,
γˆ
(m)
0 (Aq) and γˆ
(m)
C (Aq), based on simulated dataset m,
for m = 1, . . . , 1000. For simplicity, henceforth we will
refer to a general E-R model parameter γ(m)(Aq) and
corresponding estimate γˆ(m)(Aq).
Let ̂E[γˆ(Aq)] = 1M
∑M
m=1 γˆ
(m)(Aq). We compute the
average absolute bias (AAB), Empirical Standard
Deviation (ESD) and Empirical Mean Squared Error

























for q = 1, . . . , Q. Using the grids of AAB, ESD and
EMSE values thus produced, we use Simpson’s rule35,36
to calculate the integrated absolute bias, integrated
empirical SD and integrated empirical MSE for the E-R
parameter estimator. These metrics can be interpreted
as overall measures of accuracy, precision and MSE of
an estimate of the functional relationship between an
E-R model parameter and age.
Similarly, let Yqj denote the response at age, Aq,
and exposure, Cj ∈ C, where C is a grid of J = 40000
equally spaced exposures between 0 and 18. We
wish to compare the estimated expected response at
exposure level Cj , Eˆ(m)[Yqj ] = γˆ(m)0 (Aq) + γˆ
(m)
C (Aq)Cj ,
with the true expected response at Cj given by
E[Yqj ] = γ0(Aq) + γC(Aq)Cj .
Let Ê[Yqj ] = 1M
∑M
m=1 Eˆ(m)[Yqj ]. For each






















Eˆ(m)[Yqj ]− E[Yqj ]
)2
.
These evaluations produce Q× J matrices of values for
AAB, ESD, EMSE. For each Cj , for j = 1, . . . , J , we
then numerically integrate over age using Simpson’s
rule, and then apply Simpson’s rule again to integrate
over exposure to obtain the integrated absolute bias,
integrated empirical SD and integrated empirical MSE
for a patient’s expected response. These can be
interpreted as overall measures of the accuracy, precision
and MSE of our estimate of the E-R relationship across
a continuum of ages.
6.2 Measuring the accuracy of dosing rules
Following the algorithm of Section 5, we find
dosing rules comprising K = 1, . . . , 6 age groups, with
associated target exposures and minimum objective
function values. We want to assess the performance
of this dosing rule identification process. For the mth
simulated dataset we first take the derived K ‘optimal’
age groups, (a
(m)
0 = 0, a
(m)




K = 18], and
estimates of corresponding target exposure levels,
Cˆ
(m)
1 , . . . , Cˆ
(m)
K , and evaluate the true expected
response, at the target exposure levels, according to the
















for q = 1, . . . , Q, where A(m)k is the interval (a(m)k−1, a(m)k ]
and IA(m)k
(Aq) is an indicator function, which takes the
value 1 if Aq ∈ A(m)k and 0 otherwise. This measure is
the true expected response, under the simulation model,
implied by the estimated dosing rule. Comparing this
to the target response will allow us to measure the
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accuracy of our dosing rule. For each q = 1, . . . , Q and












∣∣∣∣Eˆ [Y (m)qK ]− Y ∗∣∣∣∣ .
This measure can be interpreted as the accuracy of
the K-group optimal dosing rule at age Aq. As with
Section 6.1, we calculate the integral of YqK,diff over
age using Simpson’s integration. This measure gives an
overall measure of the accuracy of the K-group optimal
dosing rule and allows us to evaluate how close the
true expected response (derived from the simulation
model) is to the target response when children are dosed
according to the estimated optimal dosing rule. We also
consider how many of the simulated datasets would lead
us to select a dosing rule with K∗ = 1, . . . ,Kmax groups,
in order to evaluate the typical complexity of optimal
dosing rules and how this varies with the extent of
differences between E-R model parameters across age
groups.
7 Results
Figures 3–5 plot the integrated absolute bias and
integrated empirical SD of E-R model parameter
estimators for each modelling approach in each
simulation scenario. For estimates obtained fitting
Bayesian penalised B-splines, bootstrapped PALM
trees, a single PALM tree and the linear model with
categorical age covariate, Supplementary Tables S2–S5,
in Supplementary Appendix C, present the integrated
average absolute bias, empirical SD (as shown in
Figures 3–5) and empirical MSE (not included in the
paper) of the estimated intercepts, slopes and expected
response.
Comparing different modelling approaches within a
scenario, Figures 3–5 suggest that, in general, estimates
of the functional relationship between the E-R model
intercept and slope parameters obtained via Bayesian
penalised B-splines are more accurate than estimates
obtained using bootstrapped PALM trees. The single
PALM tree fit is outperformed by the bootstrapped
PALM tree approach in terms of both integrated
absolute bias and empirical SD across most scenarios
and both parameters, suggesting that bootstrapping is a




















































































































































Figure 3. Integrated absolute bias (blue circles) and
integrated empirical SD (red triangles) for the E-R model
intercept. On the horizontal axis, ‘BS’ refers to the Bayesian
penalised B-splines approach, ‘Categorical’ the linear model
adjusted for a categorical age covariate, and ‘PALM’ and
‘singlePALM’ label the bootstrapped PALM tree approach and
single PALM tree, respectively.
be expected, the categorical covariate fit performs best
in terms of accuracy and precision in scenario 1, where
age groups are most distinct and follow the categories



















































































































































Figure 4. Integrated absolute bias (blue circles) and
integrated empirical SD (red triangles) for the slope of the
E-R model. On the horizontal axis, ‘BS’ refers to the Bayesian
penalised B-splines approach, ‘Categorical’ the linear model
adjusting for a categorical age covariate, and ‘PALM’ and
‘singlePALM’ label the bootstrapped PALM tree approach and
single PALM tree, respectively.
Figure 6 compares the performance of dosing rules
minimising GK under different values of K, derived
from E-R models fitted using different modelling
approaches. As the linear model adjusting for a
categorical age covariate has fixed age groups and
the single PALM tree approach estimates specific age
groupings, results for optimised dosing rules are only
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Figure 5. Integrated absolute bias (blue circles) and
integrated empirical SD (red triangles) for the expected
response. On the horizontal axis, ‘BS’ refers to the Bayesian
penalised B-splines approach, ‘Categorical’ the linear model
adjusting for a categorical age covariate, and ‘PALM’ and
‘singlePALM’ label the bootstrapped PALM tree approach and
single PALM tree, respectively.
presented for the Bayesian penalised B-splines and
bootstrapped PALM tree approaches. Figure 6 shows
that overall both Bayesian penalised B-splines and
bootstrapped PALM trees define K-group dosing rules
with a similar performance in terms of getting the
expected response close to the target response under
the simulation model. In most scenarios, there comes a
point at which there is little to be gained in terms of
accuracy by refining the dosing rule further by allowing
for additional age groups. As K increases, typically
either the true expected response (under the simulation
model and implied by the estimated dosing rule) better
matches the target response or differences between the
performances of the K-group dosing rules for ether
modelling approach diminish.
Figure 7 shows the percentage of simulations where
the global optimum dosing rule comprises K∗ age
groups for various values of K∗. It is important to note,
however, that the dosing rule age groups determined
using the algorithm defined in Section 5.2 may not
necessarily be identical to the true underlying E-R age
groups, as if there are large differences in expected
response between underlying E-R age groups, a better
fit may be achieved by dosing rules splitting age groups
around big changes and combining age groups with
smaller changes. However, it is interesting to explore the
values of K∗ defining the global optimal dosing rules to
assess their complexity. Additionally, the complexity of
the derived dosing rules will depend on the quantitative
threshold used to identify K∗ described in Section 6.2;
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Figure 6. Integrated absolute difference between the target
response and true expected response when children are dosed
according to the K group optimal dosing rule. Results are
shown for dosing rules obtained modelling the E-R relationship
using Bayesian penalised B-splines (solid blue line) and
bootstrapped PALM trees (dashed red line).
with a different threshold, c, dosing rules with different
K∗ may be selected as optimal. We find optimal dosing
rules minimising G to be cautious, forming slightly
more age groups than the underlying E-R age groups.
Focusing on Bayesian penalised B-splines, we see
from Figure 7 that in scenario 1, where larger differences
are present in the underlying E-R model parameters,
the large majority (81.6%) of simulated datasets would
lead to the investigator selecting a global optimum
dosing rule with K∗ = 4, as would a smaller majority
(54%) of datasets in scenario 3. This suggests that
when underlying E-R relationships across age groups
become less distinct, dosing rules with smaller K∗
are selected. In scenario 4, the majority of simulated
datasets would lead to the investigator selecting global
optimum dosing rules with K∗ = 4, although there is a
trend to larger K∗ compared with other scenarios. In
scenario 5, where underlying E-R model parameters do
not depend on age, a higher percentage of datasets lead
to the selection of a dosing rule defined by a smaller K∗.
Similar patterns are seen for the bootstrapped
PALM trees approach in Figure 7. It seems that both
bootstrapped PALM trees and the Bayesian penalised
B-splines approach are capable of identification of
dosing rules with multiple age groups when differences in
the underlying E-R relationships across age groups are
large, but fewer are identified as differences diminish.
For the single PALM tree fit, for scenarios where larger
differences are present in the underlying E-R model
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Figure 7. Percentage of 1000 simulations in which K∗, the
optimal number of age groups in the dosing rule, takes each
value shown. K∗ is selected according to the algorithm
described in Section 5.2 for Bayesian penalised B-spline (blue)
and bootstrapped PALM tree (pink) approaches. The values
of K∗ chosen by applying the algorithm in Section 5.2 to the
true underlying E-R relationships in each scenario are shown
by the yellow bars.
parameters, as in scenarios 1 and 2, a single PALM tree
often identifies dosing rules with four groups; 96.9% and
94.6% would choose four groups, respectively. In not one
scenario did a single PALM tree select a dosing rule with
K∗ > 4.
8 Extension to Emax model
We consider a simulated example informed by the data
presented in Marshall and Kearns37, who modelled the
relationship between cyclosporine concentration and in
vitro inhibitory effect on peripheral blood monocyte
(PBM) proliferation as a sigmoid Emax curve (2). We
simulate responses for 41 subjects assigned to one of
four age groups: 10 infants (0–1 year); 12 children (1–
4 years); 9 pre-adolescents (4–12 years); and 10 adults
(12–18 years). Data are generated such that for each of
the following concentrations of cyclosporine (6.25; 12.5;
25; 50; 100; 250; 500; 1000; and 5000 ng/mL) a patient
was recruited from each age group and the remaining
patients in each age group (1 infant; 3 children; 1
adult) were randomly assigned a concentration from this
set. Within an age group, patients’ ages are assumed
to follow a uniform distribution. In a deviation from
Marshall and Kearns37, patient responses are simulated
according to a hyperbolic Emax model (setting δ(A) ≡
1), although we follow the original publication to force
a zero intercept (γ0(A) ≡ 0). Patient responses are
simulated setting the remaining EC50 and Emax model
parameters equal to the age group specific parameter
Figure 8. Fitted curves of the relationship between log
base-10 transformed cyclosporine concentrations and PBM
proliferation based on frequentist two parameter Emax model
fit for each of the four age groups considered. Fitted curves
are the solid lines and the points are simulated data.
estimates provided by Marshall and Kearns37, and
we assume a normally distributed random error with
mean zero and variance 15. We restrict attention to a
hyperbolic Emax model because estimates of age group
specific Hill parameters are not reported by Marshall
and Kearns. Using these simulated data, we fitted a two
parameter Emax model separately to each age group.
Figure 8 shows the four fitted curves.
8.1 Bayesian penalised B-splines
We implement the Bayesian penalised B-splines model
by running three Markov chains using a thinning rate
of 3 and 9000 iterations, 4500 of which are discarded
as burn-in samples. We adopt the first-order random
walk prior defined in Section 4.3 for the penalisation.
We found a great deal of sensitivity, in terms of
convergence, to the choice of prior for the standard
deviation parameters of the random walk priors on the
B-spline coefficients of the Emax and EC50 parameters.
This sensitivity was found when using the Inverse-
Gamma priors as used in Section 6. We would advise
caution and appropriate checks to ensure posterior
results are reliable. One should check a priori the
plausible range of values for these standard deviations,
which would depend on the magnitude of the Emax
and EC50 parameters. Gamma(2, 1/A) priors, with A
large (such as A = 10) are recommended by Chung et
al. (2013)38 and the Stan user guide39 as boundary-
avoiding priors in hierarchical models for hierarchical
standard deviations. Placing Gamma(2, 0.1) priors on
the random walk prior standard deviations allowed the
two parameter Emax model to fit well to the simulated
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(a) Emax
(b) EC50
Figure 9. Plots of the Bayesian penalised B-spline and
bootstrapped MOB fits of (a) the Emax parameter and (b)
the EC50 parameter. The median of each parameter, with
2.5th and 97.5th quantiles, over the 1000 simulated bootstrap
samples and true parameter values reported by Marshall and
Kearns 37 given by the green dotted lines are also shown.
data shown in Figure 8, with the chains converging
with Gelman-Rubin convergence diagnostic < 1.011 for
all parameters.
Figure 9 shows the fitted Bayesian penalised B-spline
for the Emax and EC50 parameters over age, showing
the median, 2.5th and 97.5th quantiles. The fitted B-
splines for both the EC50 and Emax parameters seem
to follow closely to the true underlying parameter values
and, as can be seen from Figure 10a, the underlying E-R
relationships are accurately estimated. Figure 10a plots
fitted expected response against concentration in each
of the four age groups. The fitted expected response
is calculated by setting the Emax and EC50 to values
obtained by evaluating the Emax and EC50 fitted B-
splines at the mid-points of each age group.
8.2 Bootstrapped MOB
To implement the bootstrapped MOB approach, we
used the ‘mob’ function in R with a two parameter
Emax model. Otherwise, the approach proceeds exactly
as the bootstrapped PALM trees approach described
in Section 4.2. To incorporate a two parameter Emax
model in the ‘mob’ function, we built on code provided
by Thomas and Bornkamp14, using the ‘nls’ function
in R26 to specify the two parameter Emax model.
Figure 9 shows the fitted bootstrapped MOB for
the Emax and EC50 parameters over age, showing
the median, 2.5th and 97.5th quantiles over the
bootstrapped samples. The fitted Emax and EC50
parameters do change with age. However, they are
both quite far from the true underlying values. When
looking at Figure 10b we see that the model still fits
fairly well to the general shape of the data. However,
Figure 10b highlights that there is worse separation
between the fitted E-R curves for different age groups
across the whole concentration range when using the
bootstrapped MOB approach as compared with the
Bayesian penalised B-splines.
8.3 Deriving dosing rules
Following the procedure to derive optimal dosing rules
described in Section 5, Figure 11 provides a plot of the
objective function values for rules based on both the
Bayesian penalised B-splines and bootstrapped MOB
approaches. Overall, the bootstrapped MOB approach
achieves lower objective function values. For both
approaches, two age groups would almost certainly be
recommended by visual inspection.
For two age groups, the optimal age groups defining
the bootstrapped MOB dosing rule would be 0 to 3.33
years and 3.33 to 18 years, with target exposures of
191.95 and 294.87, respectively. The optimal age groups
defining the Bayesian penalised B-splines dosing rule
would be 0 to 0.84 years and 0.84 to 18 years, with
target exposures of 110.36 and 446.04, respectively. It is
interesting to note how different the dosing rules are
for these two methods: the bootstrapped MOB rule
stipulates a wider youngest age group, with larger target
exposure levels than the Bayesian penalised B-splines
rule. However, overall the bootstrapped MOB dosing
rule has a lower maximum target exposure than the
Bayesian penalised B-splines dosing rule. This seems
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(a) B-splines
(b) MOB
Figure 10. Fitted relationships between log base-10
transformed cyclosporine concentrations and PBM
proliferation based on parameter estimates for the four age
groups obtained with (a) the Bayesian penalised B-spline
approach and (b) the bootstrapped MOB approach.
Figure 11. Plot of the objective function values from the
optimisation procedure used to identify age groups for the
Bayesian penalised B-splines approach (blue line) and
bootstrapped MOB (red line).
to be indicative of the larger differences between the
age group specific E-R relationships found using the
Bayesian penalised B-splines approach.
9 Discussion
In this paper we have considered several approaches to
estimating if and how E-R model parameters change
with age in order to determine practical dosing rules
for distinct paediatric age groups. Our approaches
concentrate on the relationship between exposure and
response, deriving target exposures for age groups.
These target exposures can then be used to identify
dosing rules based on a separate relationship between
dose and exposure. We do not develop PK models
relating dose and exposure in this paper, although
many methods exist to do this40. In other therapeutic
areas, non-monotonic changes in E-R model parameters
over some age intervals may be plausible. Evaluating
the performance of our methods in these scenarios is
outside the scope of this paper, but is something that
could be investigated in future research.
We derive the target exposures for each age group
by taking the age group mid-point and finding the
exposure level at which the expected response would
be equal to the target response. In reality, this may not
actually be the optimal exposure level over the whole
age group. Rather than using the exposure appropriate
for the age group midpoint, an alternative approach
for deriving a more accurate target exposure would be
the following: within an age group, target the single
exposure level which minimises the total absolute
difference between the expected response associated
with the target exposure and the target response,
integrating over the age group. This approach is
computationally more demanding making it unsuitable
for use in our simulation study, but can be quickly
implemented for one dataset in practice.
Results of our simulations with linear E-R models
suggest that the Bayesian penalised B-splines and
bootstrapped PALM tree approaches perform similarly
in terms of estimating changes in E-R model parameters
over age, though the integrated absolute bias and
empirical SD is consistently lower in the Bayesian
penalised B-splines approach. Plots of the absolute
difference between the true expected response implied
by proposed target exposures and the target response
also suggest that for most scenarios both approaches
perform similarly, though in some scenarios Bayesian
penalised B-splines perform better than bootstrapped
PALM trees, and vice versa. In fact, the Bayesian
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penalised B-splines approach appears to outperform
all other approaches in most scenarios; only the
approach using categorical covariates sometimes has
lower integrated absolute bias, and even then, only in
scenarios where the true underlying E-R models contain
four age groups matching ICH E11 guidance (as is
assumed in the categorical covariates approach).
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11 Appendix A: Simulation scenarios in
detail
In terms of how the E-R model parameters change over
age, we consider 11 scenarios for data generation:
1. Step function relates how E-R model parameters
change over age, following ICH guidance docu-
ment age groupings with substantial differences
between E-R model parameter values in each age
group;
2. E-R model parameters have a less steep linear
transition between age groups, with parameter
values and age groups the same as scenario 1;
3. E-R model parameter values have same change
over age as in scenario 2, though now age groups
parameter values are more similar between age
groups to more closely resemble what might be
observed in reality;
4. Step function relates how E-R model parameters
change over age, as in scenario 1, but now there is
a deviation from the ICH age groups so that there
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are more distinct age groups amongst younger
children, following NICHD groupings;
5. E-R model parameters constant over all age
groups;
6. E-R model parameters have a constant linear
decrease over the whole age range;
7. Intercept term as in scenario 3, slope term
constant over age as in scenario 6;
8. Intercept term constant over age as in scenario 6,
slope term as in scenario 3;
9. Same as scenario 3, though now the true age
groups will be 0 to 6 months, 6 months to 3 years,
3 years to 11 years, 11 years to 18 years;
10. Same as scenario 3, though now the true age
groups will be 0 to 2 year, 2 year to 6 years, 6
years to 14 years, 14 years to 18 years;
11. Same as scenario 3, though now the true age
groups will be 0 to 8 years, 8 years to 12 years,
12 years to 16 years, 16 years to 18 years.
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